本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG and SHANGHAI, March 13, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or the "Group", HKEx: 2318 / 82318; SSE: 601318) took top spot in the Brand Finance Insurance 100 2025 ranking, for the ninth year in a row, boasting a brand value of US$33.6 billion. Brand Finance said that Ping An emerges as the sector's most valuable brand. This resilience is attributed to its strong brand familiarity in China and steady growth in life, health, property & casualty (P&C) insurance and accidental injury insurance. Brand Finance, a leading global brand valuation consultancy, also noted that Chinese insurance brands are making their mark on the global stage, driven by digital transformation, AI-driven innovation, and the expansion of 5G services. These brands continue to strengthen their market positions, with their strategic investments in technology and customer experience fueling brand growth. Driven by customer needs, Ping An's core businesses are showing stable growth. Ping An remains steadfast in its customer-centric approach, deepening its technology-driven "integrated finance + health and senior care" strategy and achieving stable growth in its core businesses. In the first three quarters of 2024, Ping An achieved an operating profit attributable to shareholders of the parent company of RMB113.82 billion, representing a 5.5% increase year-on-year (YoY), and operating revenue of RMB775.38 billion, a 10.0% increase YoY. The three core businesses – life and health insurance, P&C and banking – showed sustained growth, with combined operating profit attributable to shareholders of the parent company reaching RMB119.65 billion, an increase of 5.7% YoY. New business value (NBV) for the life and health insurance business reached RMB35.16 billion, up 34.1% YoY. Customers entitled to service benefits in the health and senior care ecosystem accounted for over 69.6% of the NBV of life insurance. Ping An is building world-leading AI capabilities to drive sales, improve efficiency and control risks. Ping An is focusing research and development investment in cutting-edge technologies such as generative artificial intelligence (AI) large language models. As of the end of September 2024, Ping An had a world-class technology team of over 21,000 technology developers and over 3,000 scientists. The Group's patent applications led most international financial institutions, totaling 53,521 by the end of September 2024. The number of Ping An's generative AI patent applications ranked second globally[1]. With five industry-leading laboratories and nine major databases, covering finance, healthcare, senior care and other fields, Ping An continues to adopt new technology-driven measures to promote sales, improve efficiency, and control risks. In the first three quarters of 2024, Ping An's AI service representatives interacted with customers approximately 1.34 billion times, responding to queries and resolving consumer issues quickly. They covered more than 80% of the total customer service volume in that period. At Ping An Life, smart underwriting and smart claim settlement services resulted in 93% of life insurance policies underwritten in seconds, and claims closed in an average of 7.4 minutes. The Group also continued to improve its risk management, with claims savings via smart fraud risk identification amounting to RMB9.1 billion in the first nine months of 2024. Ping An is promoting its "worry-free, timesaving, and money-saving" brand value proposition as it continues to enhance customer experience. Ping An works to make business as clear, simple and efficient as possible for customers. Ping An Auto Insurance covers 82 service items, including emergency assistance, annual inspection and designated driver services, making life simple for the 200 million users of the Ping An Auto Owner app. To save customers' time, Ping An offers one-stop services, such as Ping An Life's 1-1-1 Superfast Claim, with one-sentence reporting, one-click uploading, and one-minute validation. To save customers' money, Ping An uses professional services to achieve wealth preservation and appreciation, meeting customers' diversified needs. Ping An Bank's Credit Card for Overseas Students integrates insurance, banking, healthcare and other resources, providing a variety of preferential discounts for education, shopping, and travel. Ping An actively fulfils its social responsibilities and supports the development of the real economy. As of the end of June 2024, Ping An had cumulatively invested nearly RMB9.46 trillion to bolster the real economy, covering major national projects in energy, transportation, water conservancy, and other sectors. It also supported major strategic priorities such as the Belt and Road Initiative and the Guangdong-Hong Kong-Macao Greater Bay Area. As of the end of June 2024, Ping An's responsible investment of insurance funds reached RMB799.90 billion, including RMB124.88 billion in green investments, RMB652.56 billion in social investments, and RMB22.46 billion in inclusive investments. In the first three quarters of 2024, Ping An's green insurance premium income reached RMB37.34 billion, and its funding for rural industrial vitalization totaled RMB31.406 billion, provided to Ping An's Rural Communities Support Program. Brand Finance conducts first-hand research on over 6,000 corporate brands worldwide each year, engaging more than 175,000 respondents from 41 countries and regions. It defines brand value as the net economic benefit that a brand owner would achieve by licensing the brand in the open market. The top five in the Brand Finance Insurance 100 2025 list are Ping An, Allianz (Germany), AXA (France), China Life, and Generali (Italy). This year, 13 Chinese insurance companies were included in the world's top 100, with brand value accounting for 22.9% of the total value, ranking second globally by country. About Ping An Group Ping An Insurance (Group) Company of China, Ltd. (HKEx:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services. Under the technology-driven "integrated finance + health and senior care" strategy, the Group provides professional "financial advisory, family doctor, and senior care concierge" services to its 240 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses' quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of September 2024, Ping An had more than RMB12 trillion in total assets. The Group ranked 29th in the Forbes Global 2000 list in 2024 and 53rd in the Fortune Global 500 list in 2024. For more information, please visit www.group.pingan.com and follow us on LinkedIn - PING AN. [1] Ranked according to data on generative AI patent filings released by the World Intellectual Property Organization in 2024.
STUART, Fla., March 8, 2025 /PRNewswire/ -- Health In Tech (NASDAQ: HIT), an Insurtech platform company backed by third-party AI technology, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024, following the close of market on Monday, March 17, 2025. Health In Tech will host a conference call and live webcast to discuss the Company's financial results, recent development and business outlook. Event: Health In Tech's 2024 Fourth Quarter and Full Year Earnings Conference Call When: Monday, March 17, 2025, at 5:00 p.m. ET Live Call: PARTICIPANT DIAL IN (TOLL FREE): 1-888-346-8982PARTICIPANT INTERNATIONAL DIAL IN: 1-412-902-4272Hong Kong Toll Free: 800-905945Hong Kong-Local Toll: 852-301-84992 Webcast Link:https://event.choruscall.com/mediaframe/webcast.html?webcastid=D0BJw8tJ Replay: A webcast replay will be available on Health In Tech's investor relations website at https://healthintech.investorroom.com/ shortly after the completion of the call, and will remain available for approximately 90 day. About Health In Tech Health In Tech (Nasdaq: HIT) is an Insurtech platform company backed by third-party AI technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, and TPAs. Learn more at healthintech.com. Forward-Looking Statements Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design," "target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate," "estimate," "believe," "continue," "predict," "project," "potential," "goal," or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech's operations, results of operations, growth strategy and liquidity. Investor Contact Investor Relations:ir@healthintech.com
Histotripsy is an FDA-approved technology that offers liver cancer patients a non-invasive, painless, and highly effective treatment option HONG KONG, March 7, 2025 /PRNewswire/ -- Manulife announced today the extension of its strategic partnership with CUHK Medical Centre (CUHKMC), originally established in 2021, as part of its commitment to enhancing access to quality healthcare for its customers. Manulife is pleased to share that, through its Holistic "Medical Professional Support Service" for specified medical insurance plan[1] customers diagnosed with cancer or suspected of having cancer, it will incorporate histotripsy as a treatment option, once this treatment becomes publicly available at CUHKMC, and patients would be enrolled in clinical trials for close monitoring and evaluation of the clinical outcome. Liver cancer is the fifth most common cancer in Hong Kong, making up 4.6% of all new cancer cases in 2022.[2] Histotripsy is an FDA-approved technology that offers liver cancer patients a non-invasive, painless, and highly effective treatment option.[3] Earlier, this treatment was introduced to medical institutions in Hong Kong through donations from the Li Ka Shing Foundation. [3] "This extended partnership highlights Manulife's commitment to being a pioneering health insurance provider in Hong Kong, supporting our customers throughout their health journeys and helping to protect more lives," said Carrie Tong, Chief Operations Officer of Manulife Hong Kong and Macau. All Manulife medical plan customers are eligible for coverage of this innovative and FDA-approved histotripsy treatment, further underscoring Manulife's dedication to enhancing the quality of healthcare accessible to customers. Manulife established a strategic partnership with CUHKMC in 2021, providing eligible customers with priority access to the hospital's oncologists for a one-time, free independent medical consultation. In 2023, this partnership was expanded to offer a cashless pre-approval service for over 300 all-inclusive hospital packages, including endoscopic and surgical procedures provided by CUHKMC. Manulife has extended its strategic partnership with CUHK Medical Centre to incorporate histotripsy into its holistic “Medical Professional Support Service”. About Manulife Hong Kong Manulife Hong Kong has been a trusted name for more than 125 years. Since our operations started in Asia in 1897, we have grown to become one of the top-tier providers of financial services, offering a diverse range of protection and wealth products and services to over 2.6 million customers in Hong Kong and Macau. We are committed to helping make decisions easier and lives better for our customers. Manulife Hong Kong, through Manulife International Holdings Limited, owns Manulife (International) Limited, Manulife Investment Management (Hong Kong) Limited, and Manulife Provident Funds Trust Company Limited. These entities are all subsidiaries of Manulife Financial Corporation. About Manulife Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as 'MFC' on the Toronto, New York, and the Philippine stock exchanges, and under '945' in Hong Kong. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com. [1] Terms and conditions apply. Eligibility to Holistic "Medical Professional Support Service" applies to customers of Manulife Supreme VHIS Flexi Plan, Manulife Supreme Lite VHIS Supplementary Benefit, Manulife Supreme Medical Plan, Manulife Supreme Lite Medical Supplementary Benefit, ManuMaster Healthcare Series/Benefit, and ManuShine Healthcare Series/Benefit. The content of this press release does not contain all the terms and conditions of policies, and the full terms and conditions are set out in the policy documents. ManuMaster Healthcare Series/Benefit and ManuShine Healthcare Series/Benefit are available as basic plans or supplementary benefits. [2] Figures from the Centre for Health Protection under the HKSAR Department of Health. [3] "Li Ka Shing Foundation funds non-invasive liver cancer treatment for Hong Kong patients" (SCMP, Aug 27, 2024)
~ Launching New Insurance Experience Integrating Payments and Insurance in Summer 2025 TOKYO, March 6, 2025 /PRNewswire/ -- Smartpay Corporation (Headquarters: Minato-ku, Tokyo; Sam Pemberton-Ahmed, CEO and Founder of Smartpay; hereinafter "the Company"), provider of the "Smartpay" Buy Now Pay Later service, announces the launch of embedded insurance products in the Japanese market, following one year of partnership with Chubb Insurance Japan (Headquarters: Shinagawa-ku, Tokyo; President: Edward Kopp; hereinafter "Chubb Japan"), the Japanese subsidiary of Chubb Group, a world leader in insurance. Current Challenges in the Insurance Industry The traditional insurance industry faces challenges in meeting the evolving needs of modern consumers. Insurance contracting still largely relies on paper-based analog processes, leaving significant room for improvement in digitalization, personalization, real-time capabilities, and security. According to the Ministry of Economy, Trade and Industry survey[1], cashless payments now account for approximately 50% of consumer monthly spending, with widespread adoption of diverse payment methods including credit cards and electronic money. The insurance industry has an opportunity to enhance consumer experience by embracing digitalization to capitalize on this trend. Changes in the insurance industry are becoming evident across various sectors. For example, Japan's travel insurance market reached $678 million (approximately ¥101.7 billion) in 2023 and is projected to grow to $1.523 billion (approximately ¥228.5 billion) by 2028[2]. Furthermore, post-pandemic surveys indicate that 47% of Japanese travelers are seeking new ways to purchase travel insurance that differ from traditional methods[3]. Additionally, Generation Z consumers tend to prioritize convenience and speed in payment experiences and dislike complicated procedures[4]. These changes in young consumers' behavior are driving the demand for embedded insurance that can be completed with simple operations. What is Embedded Insurance? Embedded insurance is a mechanism that provides insurance seamlessly integrated into the payment process when consumers purchase products or services. For example, this includes options to purchase travel insurance simultaneously when buying airline tickets online. This method simplifies the insurance application process and enables appropriate coverage to be provided at the optimal timing for consumers. Through its partnership with Chubb Japan, Smartpay is bringing innovation to the insurance industry. By providing solutions at the moment of need, we are transforming the nature of insurance. Our embedded insurance technology is seamlessly integrated into the payment process, providing appropriate coverage instantly when customers need it. Growth Outlook for the Embedded Insurance Market The global embedded insurance market size is projected to grow CAGR of 11.6% from 2024 to 2030, reaching approximately $175.25 billion (about ¥26.3 trillion) by 2030[5]. Another report predicts the embedded insurance market will grow at an annual rate of 4.8% from 2025 to 2032[6]. By region, the Asia-Pacific region is the largest market, accounting for approximately 39% of share. This is followed by Europe at 32% and North America at 21%. By product type, life insurance is the largest segment, accounting for 51% of share. By application, the automotive sector is the largest, accounting for approximately 26% of share. These data suggest that the embedded insurance market will continue to show steady growth. Fusion of Technological Innovation and Customer-Centric Design Embedded insurance goes beyond simply incorporating insurance at the point of payment, achieving comprehensive fintech innovation. It combines the following: Real-time Risk Assessment and Dynamic Pricing - A system that provides optimal coverage and pricing for each customer, often making it possible to keep insurance premiums lower Highly Secure Complex Infrastructure - Integration of Smartpay's payment system and Chubb's insurance infrastructure Seamless Customer Experience - Eliminating complicated procedures, enabling appropriate insurance enrollment at the time of purchase with intuitive and user-friendly experience. Strategic Partnership with Chubb Chubb is a global company with a track record of successful partnerships with major financial institutions worldwide. In 2018, it partnered with Grab, Southeast Asia's largest super app, to provide insurance products to millions of Grab users. Additionally, it has led digital transformation and technological innovation in the insurance industry, such as partnering with Nubank, Brazil's largest digital bank, to provide fully digitalized life insurance. In this context, Chubb's selection of Smartpay as its first embedded insurance business partner in Japan demonstrates strong confidence in our innovative approach, technological capabilities, and market potential. Smartpay to Launch First Embedded Insurance Product in Summer 2025 Smartpay and Chubb Japan plan to provide their first embedded insurance product in BNPL in partnership with Fútbol Opción, a soccer cultural exchange program provider operated by Actif LLC, in summer 2025. While soccer cultural exchange programs represent a significant investment for families, Smartpay's installment payment option makes it possible to realize children's dreams while reducing the burden on household finances. Additionally, having insurance coverage during international travel is a crucial element for parents' peace of mind. Through this partnership, families can now handle both program fee installments and insurance enrollment in one process, making soccer exchange opportunities accessible to more young people. Additionally, Smartpay announced details of this initiative at the "Global Financial Technology Network Forum" held in March 2025. About Smartpay Smartpay is a fintech company that develops and provides smart solutions to help consumers manage their daily expenses and improve their financial well-being. In addition to realizing Japan's first one-click credit card-based BNPL solution, Smartpay was the first in Japan to introduce "Smartpay Bank Direct" enabling immediate withdrawals from bank accounts[8]. Through Smartpay Bank Direct, developed in partnership with the Japan Electronic Payment Promotion Organization (JEPPO), we provide payment services accessible to 90% of the population with bank accounts, partnering with 20 major banks including megabanks and over 200 credit unions in Japan. For more information, please visit https://smartpay.co/. In addition, Smartpay is also focusing on unprecedented initiatives, such as being the first BNPL solution in Japan to establish processor agreements with both Adyen and Stripe[9], in order to pursue convenience for both businesses and consumers. About Chubb Japan Chubb Japan provides innovative property and casualty insurance products to both individuals and corporations, based on innovative thinking and Chubb Group's global network. With a history in Japan reaching its 100th anniversary in 2020, it has the longest presence among foreign property and casualty insurance companies. It has received an "AA-" rating for both insurance financial strength and issuer credit rating from U.S. rating agency Standard & Poor's (as of March 2025). About Chubb Group and Chubb Limited Chubb is a world leader in insurance. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. The company is defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb employs approximately 43,000 people worldwide. 1: Ministry of Economy, Trade and Industry Commerce and Service Group Cashless Promotion Office, "Consumer Survey Analysis Results" https://www.meti.go.jp/shingikai/mono_info_service/cashless_future/pdf/005_05_00.pdf 2: Japan Travel Insurance Market (2023-2028) https://www.researchandmarkets.com/reports/5566829/japan-travel-insurance-market-2023-2028-by 3: Research shows Japanese travelers desire embedded protection and improved claims experiences in a post-pandemic world https://covergenius.com/embedded-insurance-travel-japan/ 4: Deloitte Tohmatsu Group, "2024 Domestic Generation Z Awareness and Purchase Behavior Survey" https://www2.deloitte.com/jp/ja/pages/consumer-business/articles/cp/generationz-behavior-survey.html 5:Global Embedded Insurance Market Size, Share, and Trend Analysis Research Report 2024-2030 https://newscast.jp/news/5752394 6: Global Embedded Insurance Market Research Report 2024 https://www.reliableresearchtimes.com/embedded-insurance-r1837378 7,9: As a BNPL service in Japan that utilizes credit card's credit limit (as of November 2021) 8: As a "BNPL service that connects with Bank Pay and allows for immediate withdrawal from bank accounts in Japan" (as of December 2022)
- XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's commercial presence in APAC. To date, XPOVIO® has been approved for multiple indications in ten markets across the APAC region. - XPOVIO® has been approved for health insurance coverage in the mainland of China, Taiwan market, Australia, Singapore and South Korea. SHANGHAI and HONG KONG, March 5, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Indonesia National Agency of Drug and Food Control (BPOM) has approved a New Drug Application (NDA) for XPOVIO® (selinexor) for three indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy;(2) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors (PIs), at least two immunomodulatory agents (IMiDs), and an anti‐CD38 monoclonal antibody; and (3) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy who are not eligible for haematopoietic cell transplant. With a novel mechanism of action, XPOVIO® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). The ASEAN region, with its steady economic growth and a population exceeding 600 million, has become a market of significant potential for global biomedical development. The accelerating aging population in ASEAN has increased the overall disease burden on patients and local communities, leading to a growing demand for novel therapeutics. Currently, Antengene is actively expanding its presence into APAC markets in efforts to introduce more innovative medicines to the ASEAN region in the future, improving the level of healthcare in these regions and benefiting more patients in need. While bringing XPOVIO® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About XPOVIO® (selinexor) XPOVIO® is the world's first approved orally-available, selective inhibitor of the nuclear export protein XPO1. It offers a novel mechanism of action, synergistic effects in combination regimens, fast onset of action, and durable responses. By blocking the nuclear export protein XPO1, XPOVIO® can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. XPOVIO® delivers its antitumor effects through three mechanistic pathways: 1) exerting antitumor effects by inducing the intranuclear accumulation of tumor suppressor proteins; 2) reducing the level of oncogenic proteins in the cytoplasm by inducing the intranuclear accumulation of oncogenic mRNAs; 3) restoring hormone sensitivity by activating the glucocorticoid receptors (GR) pathway. To utilize its unique mechanism of actions, XPOVIO® is being evaluated for use in multiple combination regimens in a range of indications. At present, Antengene is conducting multiple clinical studies of XPOVIO® in the mainland of China for the treatment of relapsed/refractory hematologic malignancies and solid tumors (3 of these studies are being jointly conducted by Antengene and Karyopharm Therapeutics Inc. [Nasdaq:KPTI]). About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.comMobile: +86 13062747000
A12 藝術空間
Health Insurance
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
